Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of SAGE Therapeutics patents

Patents where

Current Assignee

Name

SAGE Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10246482 Neuroactive steroids, compositions, and uses thereof	Patent 10246482 was granted and assigned to SAGE Therapeutics on April, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10246482	April 2, 2019
‌ US Patent 9512165 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof	Patent 9512165 was granted and assigned to SAGE Therapeutics on December, 2016 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	9512165	December 6, 2016
‌ US Patent 9725481 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof	Patent 9725481 was granted and assigned to SAGE Therapeutics on August, 2017 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	9725481	August 8, 2017
‌ US Patent 9365611 19-NOR neuroactive steroids and methods of use thereof	Patent 9365611 was granted and assigned to SAGE Therapeutics on June, 2016 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	9365611	June 14, 2016
‌ US Patent 11261211 19-NOR neuroactive steroids and methods of use thereof	Patent 11261211 was granted and assigned to SAGE Therapeutics on March, 2022 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11261211	March 1, 2022
‌ US Patent 10259840 Oxysterols and methods of use thereof	Patent 10259840 was granted and assigned to SAGE Therapeutics on April, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10259840	April 16, 2019
‌ US Patent 10377790 19-nor neuroactive steroids and methods of use thereof	Patent 10377790 was granted and assigned to SAGE Therapeutics on August, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10377790	August 13, 2019
‌ US Patent 11236121 Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid	Patent 11236121 was granted and assigned to SAGE Therapeutics on February, 2022 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11236121	February 1, 2022
‌ US Patent 10577390 Compositions and methods for treating CNS disorders	Patent 10577390 was granted and assigned to SAGE Therapeutics on March, 2020 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10577390	March 3, 2020
‌ US Patent 11905309 Neuroactive steroids and methods of use thereof	Patent 11905309 was granted and assigned to SAGE Therapeutics on February, 2024 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11905309	February 20, 2024
‌ US Patent 11884697 Oxysterols and methods of use thereof	Patent 11884697 was granted and assigned to SAGE Therapeutics on January, 2024 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11884697	January 30, 2024
‌ US Patent 10940156 Neuroactive steroids, compositions, and uses thereof	Patent 10940156 was granted and assigned to SAGE Therapeutics on March, 2021 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10940156	March 9, 2021
‌ US Patent 12129275 Neuroactive steroids, compositions, and uses thereof	Patent 12129275 was granted and assigned to SAGE Therapeutics on October, 2024 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	12129275	October 29, 2024
‌ US Patent 11279730 Oxysterols and methods of use thereof	Patent 11279730 was granted and assigned to SAGE Therapeutics on March, 2022 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11279730	March 22, 2022
‌ US Patent 11554125 Neuroactive steroids, compositions, and uses thereof	Patent 11554125 was granted and assigned to SAGE Therapeutics on January, 2023 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11554125	January 17, 2023
‌ US Patent 11111266 Oxysterols and methods of use thereof	Patent 11111266 was granted and assigned to SAGE Therapeutics on September, 2021 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11111266	September 7, 2021
‌ US Patent 11149054 Oxysterols and methods of use thereof	Patent 11149054 was granted and assigned to SAGE Therapeutics on October, 2021 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11149054	October 19, 2021
‌ US Patent 10201550 Oxysterols and methods of use thereof	Patent 10201550 was granted and assigned to SAGE Therapeutics on February, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10201550	February 12, 2019
‌ US Patent 11426417 Neuroactive steroid formulations and methods of treating CNS disorders	Patent 11426417 was granted and assigned to SAGE Therapeutics on August, 2022 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11426417	August 30, 2022
‌ US Patent 11926646 C7 substituted oxysterols and methods of use thereof	Patent 11926646 was granted and assigned to SAGE Therapeutics on March, 2024 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11926646	March 12, 2024
‌ US Patent 10322139 Neuroactive steroid formulations and methods of treating CNS disorders	Patent 10322139 was granted and assigned to SAGE Therapeutics on June, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10322139	June 18, 2019
‌ US Patent 11396525 C17, C20, and C21 substituted neuroactive steroids and their methods of use	Patent 11396525 was granted and assigned to SAGE Therapeutics on July, 2022 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11396525	July 26, 2022
‌ US Patent 11851457 Oxysterols and methods of use thereof	Patent 11851457 was granted and assigned to SAGE Therapeutics on December, 2023 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11851457	December 26, 2023
‌ US Patent 11878995 Oxysterols and methods of use thereof	Patent 11878995 was granted and assigned to SAGE Therapeutics on January, 2024 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	11878995	January 23, 2024
‌ US Patent 10227375 Neuroactive steroids and methods of use thereof	Patent 10227375 was granted and assigned to SAGE Therapeutics on March, 2019 by the United States Patent and Trademark Office.	SAGE Therapeutics	SAGE Therapeutics	United States Patent and Trademark Office	10227375	March 12, 2019

Results per page:

73 results

0 selected

73 results

0 selected